Viking Therapeutics General and Administrative Expenses 2011-2026 | VKTX

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses Viking Therapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
48.4 M	49.3 M	37 M	16.1 M	10.7 M	10.7 M	9.13 M	7.12 M	5.33 M	4.85 M	5.03 M	1.24 M	89.5 K	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
49.3 M	89.5 K	15.8 M

Quarterly General and Administrative Expenses Viking Therapeutics

2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
14.4 M	14.1 M	-	13.8 M	10.3 M	9.97 M	-	8.89 M	9.82 M	9.53 M	-	4.24 M	4.09 M	3.69 M	-	2.61 M	2.74 M	2.69 M	-	2.73 M	2.83 M	2.96 M	-	2.16 M	2.24 M	2.31 M	-	1.71 M	1.7 M	1.76 M	-	1.23 M	1.27 M	1.44 M	-	1.16 M	1.21 M	1.39 M	-	1.78 M	1.53 M	322 K	-	360 K	514 K	160 K	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
14.4 M	160 K	4.1 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	78.3 M	-	2.43 %	$ 254 M	Germany
ARCA biopharma ABIO	13.1 M	-	1052.0 %	$ 415 M	USA
Acasti Pharma ACST	7.17 M	-	4.01 %	$ 150 M	Canada
AC Immune SA ACIU	17.9 M	$ 2.72	7.51 %	$ 229 M	Schweiz
Adverum Biotechnologies ADVM	63.1 M	-	-	$ 86.2 M	USA
AgeX Therapeutics AGE	9.33 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	47.9 M	-	-	$ 1.01 B	USA
AIkido Pharma AIKI	29.7 M	-	1.93 %	$ 17.4 M	USA
Aptorum Group Limited APM	5.41 M	$ 0.81	1.28 %	$ 4.42 M	China
I-Mab IMAB	900 M	-	-	$ 866 M	China
argenx SE ARGX	308 M	$ 840.28	1.7 %	$ 25 B	Niderland
Ascendis Pharma A/S ASND	160 M	$ 234.99	0.02 %	$ 5 B	Danmark
Alexion Pharmaceuticals, Inc. ALXN	1.4 B	-	-	$ 40.3 B	USA
Akero Therapeutics AKRO	37.9 M	-	-	$ 3.67 B	USA
Biophytis SA BPTS	7.15 M	-	-13.47 %	$ 169 M	France
Albireo Pharma ALBO	69.6 M	-	-0.23 %	$ 916 M	USA
Alterity Therapeutics Limited ATHE	5.51 M	$ 3.33	0.79 %	$ 8.01 B	Australia
Atea Pharmaceuticals AVIR	48.8 M	$ 4.65	1.31 %	$ 392 M	USA
Allena Pharmaceuticals ALNA	12.7 M	-	3.16 %	$ 1.9 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	4.66 M	-	-1.52 %	$ 24.7 M	USA
AlloVir ALVR	42.9 M	-	4.14 %	$ 49.1 M	USA
Midatech Pharma plc MTP	4.95 M	-	-18.52 %	$ 27.3 M	Britain
Akouos AKUS	22.2 M	-	0.23 %	$ 488 M	USA
BioVie BIVI	8.57 M	$ 1.25	-	$ 1.85 M	USA
Ampio Pharmaceuticals AMPE	7.08 M	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	37.4 M	-	-	$ 10.1 M	USA
BioMarin Pharmaceutical BMRN	1.01 B	$ 62.62	-0.48 %	$ 11.9 B	USA
Acorda Therapeutics ACOR	89.7 M	-	-24.86 %	$ 820 K	USA
Acer Therapeutics ACER	12.7 M	-	2.71 %	$ 14 M	USA
Aravive ARAV	13 M	-	-13.39 %	$ 1.45 M	USA
Capricor Therapeutics CAPR	12.8 M	$ 27.91	0.14 %	$ 747 M	USA
Институт стволовых клеток человека ISKJ	25.8 M	-	-	-	Russia
CASI Pharmaceuticals CASI	23.8 M	$ 0.8	5.68 %	$ 109 M	USA
Applied Genetic Technologies Corporation AGTC	17 M	-	-	$ 26.5 M	USA
Avenue Therapeutics ATXI	4.64 M	-	-52.27 %	$ 4.45 M	USA
Catalyst Biosciences CBIO	14.7 M	$ 12.65	10.29 %	$ 833 M	USA
Axsome Therapeutics AXSM	63.3 M	$ 169.95	-2.75 %	$ 8.45 B	USA
Ayala Pharmaceuticals AYLA	1.53 M	-	-	$ 7.46 M	Israel
Atreca BCEL	31.5 M	-	-11.76 %	$ 5.79 M	USA
Alpine Immune Sciences ALPN	18 M	-	-	$ 2.17 B	USA
BioDelivery Sciences International BDSI	106 M	-	-4.8 %	$ 255 M	USA
Aeterna Zentaris AEZS	5.92 M	-	5.93 %	$ 314 M	Canada
BeiGene, Ltd. BGNE	1.83 B	-	0.49 %	$ 251 B	Cayman-islands
Biogen BIIB	2.43 B	$ 195.13	-0.62 %	$ 28.6 B	USA
Cellectis S.A. CLLS	37.9 M	$ 3.98	0.51 %	$ 116 M	France
Bellicum Pharmaceuticals BLCM	5.72 M	-	-9.72 %	$ 5.89 M	USA
Baudax Bio BXRX	24.1 M	-	0.59 %	$ 63 K	USA
Aptose Biosciences APTO	11.2 M	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	19.8 M	-	-39.0 %	$ 4.57 M	USA
Cellectar Biosciences CLRB	11.7 M	$ 3.36	3.07 %	$ 41.1 M	USA